- Home
- SAFE vs ARDX Comparison
SAFE vs ARDX Comparison
Compare SAFE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- ARDX
- Stock Information
- Founded
- SAFE 2016
- ARDX 2007
- Country
- SAFE United States
- ARDX United States
- Employees
- SAFE N/A
- ARDX N/A
- Industry
- SAFE Real Estate Investment Trusts
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- ARDX Health Care
- Exchange
- SAFE Nasdaq
- ARDX Nasdaq
- Market Cap
- SAFE 1.4B
- ARDX 1.2B
- IPO Year
- SAFE 2017
- ARDX 2014
- Fundamental
- Price
- SAFE $20.75
- ARDX $4.75
- Analyst Decision
- SAFE Buy
- ARDX Buy
- Analyst Count
- SAFE 9
- ARDX 7
- Target Price
- SAFE $28.44
- ARDX $11.75
- AVG Volume (30 Days)
- SAFE 287.1K
- ARDX 3.4M
- Earning Date
- SAFE 02-10-2025
- ARDX 10-31-2024
- Dividend Yield
- SAFE 3.38%
- ARDX N/A
- EPS Growth
- SAFE N/A
- ARDX N/A
- EPS
- SAFE 1.70
- ARDX N/A
- Revenue
- SAFE $401,069,000.00
- ARDX $251,849,000.00
- Revenue This Year
- SAFE N/A
- ARDX $168.07
- Revenue Next Year
- SAFE $6.21
- ARDX $15.16
- P/E Ratio
- SAFE $12.36
- ARDX N/A
- Revenue Growth
- SAFE 23.33
- ARDX 87.57
- 52 Week Low
- SAFE $17.91
- ARDX $4.34
- 52 Week High
- SAFE $28.80
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- SAFE 46.86
- ARDX 34.51
- Support Level
- SAFE $20.20
- ARDX $5.18
- Resistance Level
- SAFE $21.24
- ARDX $5.47
- Average True Range (ATR)
- SAFE 0.51
- ARDX 0.32
- MACD
- SAFE 0.07
- ARDX -0.07
- Stochastic Oscillator
- SAFE 40.59
- ARDX 3.28
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that is net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.